Biosimilar Filgrastim in Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization and Post-Transplant Hematologic Recovery

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|23|21|2217-2229

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.23, Iss.21, 2016-08, pp. : 2217-2229

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

To date, two kinds of Granulocyte Colony-Stimulating Factors (G-CSF) have beenapproved for autologous peripheral blood hematopoietic stem cell (PBSCs) mobilization and posttransplanthematologic recovery after high-dose chemotherapy: filgrastim (originator andbiosimilar) and lenograstim. Biosimilar filgrastim has been approved on the basis of comparableefficacy and safety in clinical studies where it has been used as chemotherapy-induced febrileneutropenia prophylaxis, but no specific pre-registration studies have been published in thetransplant setting. Hence, there is still general skepticism about the role of biosimilar G-CSFs inthis setting of patients. This review of biochemical, pre-clinical and clinical data suggestssignificant comparability of biosimilar filgrastim with both originator filgrastim and lenograstim inautologous PBSCs mobilization and post-autograft hematologic recovery.